Title |
Metformin targets multiple signaling pathways in cancer
|
---|---|
Published in |
Cancer Communications, January 2017
|
DOI | 10.1186/s40880-017-0184-9 |
Pubmed ID | |
Authors |
Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang, Yi Lu |
Abstract |
Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Panama | 1 | 25% |
Spain | 1 | 25% |
United States | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 146 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 28 | 19% |
Student > Bachelor | 22 | 15% |
Student > Ph. D. Student | 18 | 12% |
Researcher | 8 | 5% |
Lecturer | 7 | 5% |
Other | 24 | 16% |
Unknown | 39 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 36 | 25% |
Biochemistry, Genetics and Molecular Biology | 28 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 14 | 10% |
Agricultural and Biological Sciences | 9 | 6% |
Nursing and Health Professions | 4 | 3% |
Other | 13 | 9% |
Unknown | 42 | 29% |